NCT06159790 2026-03-04
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sandoz
Phase 3 Suspended
Clinical Trials
14 trialsNCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
NCT06388902 2025-11-21
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT05938296 2025-11-19
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
Phase 1 Suspended
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT04693546 2025-09-26
PREVENT
Metabiomics Corp
Suspended
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT05055518 2025-06-27
APL-102 Capsule in Patients With Advanced Solid Tumors
Apollomics Inc.
Phase 1 Suspended
NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NCT05603572 2025-06-05
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Primocure Pharma
Phase 1/2 Suspended
NCT02354547 2025-05-30
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT05571969 2025-05-07
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Suspended